Crossmark

Astragaloside IV ameliorates cardiomyocyte injury and heart failure through hif/rho/rock pathway regulation: In vitro and in vivo insights

Published Online: 2025-10-14

Authors

Li, Gang

Wang, Min

Dong, Qiufen

Li, Dan

Liu, Juan

Long, Qi

Ding, Yanbing
Funding

Funding for this research was provided by:

Hubei Provincial Administration of Traditional Chinese Medicine (ZY2023M002, ZY2023M002, ZY2023M002, ZY2023M002, ZY2023M002, ZY2023M002, ZY2023M002)

Hubei Provincial Natural Science Foundation Innovation and Development Joint Fund Project (2022CFD158, 2022CFD158, 2022CFD158, 2022CFD158, 2022CFD158, 2022CFD158, 2022CFD158)
License Information

Text and Data Mining valid from 2025-10-14

Version of Record valid from 2025-10-14
More Information

Article History

Received: 11 March 2025

Accepted: 23 July 2025

First Online: 14 October 2025

Declarations

:

: The authors declare no competing interests.

: The study protocol was approved by the Ethics Committee of Hubei Provincial Hospital of Traditional Chinese Medicine (HDSZYY-2020-01305). All methods were carried out in accordance with relevant guidelines and regulations. All methods are reported in accordance with ARRIVE guidelines.

: Not applicable.

Document is current